Over 100 pages

Over 60 tables and figures

Published Feb 2020

 

  •        - Increase your foothold in the Chinese market TODAY

 

  •        - Establish partnerships to manufacture, distribute or develop Chinese products

 

  •        - Scope out the market prior to entry

 

 

This new GMR Data report covers the length and breadth of the China Pharmaceutical sector. Every news service globally is focused on COVID-19 (“Coronavirus”) and how it will affect the global population, but what of the China health system itself? How does the sector operate during ’normal’ times?

 

What will drive and restrain the Chinese health markets?

 

Increase in Non-Communicable Disease (NCD)

Elderly population

Expanding Middle Class

Governmental Policy / Trade War

Industry Harmonization with Global Markets

 

GMR Data view that the Chinese pharmaceutical sector is set for substantial growth across the next decade as an increasing middle class, which has greater access to healthcare, is set to drive the domestic market significantly. A growing population, which is tilted towards the middle aged and elderly, is another factor that will boost Chinese healthcare and pharmaceutical markets.

 

China is the largest supplier of raw materials to that produce high-priced, non-generic drugs produced by the US, with an ongoing Trade war Chinese pharmaceuticals face tariffs; this is likely to strengthen the domestic (Chinese) pharmaceutical market in the short to mid-term.

 

China became a member of the International Council for Harmonization in 2017 and accepted declarations in clinical trials/ approvals by the US FDA and the EMA, shortening clinical trial authorization processes significantly in China.

 

So this mix of factors; growing, more affluent population, closer regulatory harmonisation, foreign market entrance etc. is expected to drive the China Pharmaceutical market. There will of course be variables - Whilst there is the huge focus on Covid-19, this will likely disrupt the flow of raw pharmaceuticals products to the US, only last week CNN covered the story Coronavirus outbreak in China could lead to 'critical' shortages of medical products in the US.

 

On the other hand the outbreak will cause an uptick in domestic (China) sales of pharmaceutical products (both Rx and OTC), medical devices, medical consumables etc. It is a very interesting time for the Chinese Pharmaceutical sector.

 

This GMR Data report is the single tool to equip you with the latest trends in the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.

 

With over 100 pages, and over 60+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

 

To order this report today get in touch via info@gmrdata.com or go to gmrdata.com